STAT News called Revolution Medicines' pancreatic cancer drug 'one of the most exciting cancer medicines in years.' With Phase 3 data showing roughly doubled survival and a plenary slot at ASCO 2026, this could be the biggest moment in pancreatic cancer treatment in decades.
Pancreatic cancer has been oncology's cruelest riddle for decades. Only about 13% of patients survive five years. More than half are diagnosed after the cancer has already spread, and at that point the five-year survival rate drops to roughly 3%. Chemotherapy buys months, not years. Immunotherapy barely moves the needle. And the one gene responsible for almost all of it? Scientists spent 40 years calling it "undruggable."
That gene is KRAS. It's mutated in roughly 90 to 95% of pancreatic cancers, making it the single most important driver of the disease. Think of KRAS as a light switch stuck in the "on" position, constantly telling cancer cells to grow and divide. For decades, drug designers couldn't find a way to flip it off. The protein's surface was too smooth, too slippery, too featureless for a small molecule to grab onto.
Revolution Medicines thinks it finally cracked the code. And ahead of ASCO 2026 (the biggest cancer research conference on the planet), STAT News called its lead drug "one of the most exciting cancer medicines in years."
A Drug That Nearly Doubled Survival
The drug is called daraxonrasib. Instead of targeting the inactive form of KRAS (the approach older drugs took), it attacks the protein while it's switched on, actively driving tumor growth. Revolution calls this a "RAS(ON)" inhibitor, and the key advantage is coverage: daraxonrasib hits multiple KRAS mutations at once, not just one rare variant.
That matters enormously in pancreatic cancer. The most common KRAS mutations here are G12D (about 35 to 45% of cases) and G12V (around 20 to 30%). Earlier KRAS drugs like sotorasib and adagrasib only target G12C, a mutation found in a tiny 1 to 2% of pancreatic tumors. Those drugs changed the game in lung cancer but were basically irrelevant for the pancreas.
Daraxonrasib's pivotal trial, RASolute 302, enrolled patients with metastatic pancreatic cancer whose disease had progressed after prior chemotherapy. One arm got the oral pill daily; the other got standard intravenous chemo. In April 2026, the results came in: daraxonrasib delivered roughly a compared to chemo. The company described it as approximately doubling survival in this setting.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
six-month improvement in median overall survival
For context, second-line metastatic pancreatic cancer patients typically survive around 8 to 12 months with current treatments. Doubling that would be like going from a coin-flip survival window to something that actually gives patients time.
Why ASCO Could Be the Main Event
Revolution scored one of the most coveted slots at ASCO 2026: a plenary session late-breaking presentation on May 31st (abstract LBA5). Plenary spots are the keynote speeches of cancer research. They're reserved for data the conference organizers believe could change how doctors treat patients.
The company had already previewed some data at AACR 2026 in April, showing strong activity for daraxonrasib in first-line metastatic pancreatic cancer as well, both as a single agent and combined with chemotherapy. Eileen O'Reilly, M.D., of Memorial Sloan Kettering presented one set of results. Brian Wolpin, M.D., presented the other.
The ASCO plenary will focus on the full Phase 3 data from RASolute 302. If the detailed results hold up under peer scrutiny, this could be the moment daraxonrasib transitions from exciting clinical story to new standard of care. Revolution has already said it's preparing global regulatory submissions, and the drug was selected for the FDA Commissioner's National Priority Voucher pilot program to speed up review.
Wall Street Is Already a Believer
Revolution Medicines' stock tells its own story. Shares have soared from the mid-$30s to around $150 over the past year, pushing the company's market cap north of $31 billion. Analyst consensus is firmly bullish: MarketBeat shows 4 Strong Buy and 15 Buy ratings against just one lone Sell.
Recent price target bumps tell you where the momentum is heading. Piper Sandler raised its target to $172. Another analyst pushed to $165. The freshest batch of targets from MarketWatch and the Wall Street Journal cluster around a median of $175 and a high of $263, suggesting Wall Street sees more room to run if the ASCO data deliver.
The bear case isn't trivial, though. Some older analyst models still have targets in the $100 to $125 range, and a noted insider sale of about $18 million in mid-April raised a few eyebrows. Wide target ranges (the low end sits at $116) reflect the binary nature of late-stage oncology bets: spectacular data could send shares toward $200-plus, while disappointment could knock 20 to 30% off the stock.
The Competition Is Playing Catch-Up
Revolution isn't alone in chasing RAS, but it has a significant head start in pancreatic cancer. Eli Lilly has its drug olomorasib, but as a KRAS G12C-specific inhibitor applicable to only 1 to 2% of PDAC patients, it is a niche player rather than a direct rival in the broader pancreatic cancer market. Analysts estimate Revolution is 12 to 18 months ahead in this specific indication. Incyte has an early-stage KRAS G12D inhibitor showing roughly 80% disease control in heavily pretreated patients, but it's still in Phase 1. Companies like BridgeBio and Immuneering are even further back.
As for the original KRAS G12C drugs from Amgen and Bristol Myers Squibb (which acquired Mirati)? They're essentially niche players in pancreatic cancer. When your drug targets a mutation found in fewer than 3% of patients, you're fishing in a very small pond.
Revolution also has a deeper bench than most competitors realize. Beyond daraxonrasib, the company is developing allele-specific RAS(ON) inhibitors: zoldonrasib for G12D, RMC-5127 for G12V, and elironrasib for G12C. That portfolio sets up future combination strategies designed to overcome the resistance that eventually limits any single targeted therapy.
What This Means for Patients
Pancreatic cancer has been the disease where hope goes to die. Five-year survival has crawled from about 6% a decade ago to 13% today. Progress has been painfully slow, measured in weeks rather than years of additional life.
Daraxonrasib's Phase 3 results represent the first time a RAS-targeted drug has shown a substantial survival benefit in pancreatic cancer. The trial also showed activity in patients without RAS mutations, hinting at broader reach than anyone expected. Revolution is now running additional Phase 3 trials aiming to cover the full spectrum of the disease.
The full data presentation at ASCO on May 31st will be the real test. Plenary sessions attract thousands of oncologists, and the scrutiny will be intense. But if the numbers hold, pancreatic cancer patients may finally have something they've been waiting decades for: a drug that treats the root cause of their disease, not just the symptoms. An oral pill instead of IV chemo. And a real shot at more time.
Clinical & Regulatory
5 min read
The 100% Tax That Could Break Big Pharma's Global Playbook
The Trump administration just slapped a 100% tariff on every branded drug not made in America, forcing pharma companies into an impossible choice: slash prices, build U.S. factories, or watch their margins evaporate. The biggest shake-up in pharma trade policy is already reshaping the industry.
